CARTESIAN THERAPEUTICS INC (RNAC)
Health Care · Cell therapy for autoimmune diseases · NASDAQ
Cartesian Therapeutics is pioneering mRNA-engineered cell therapies designed to provide a precision immune reset for patients with autoimmune diseases, administered in an outpatient setting without the need for lymphodepleting chemotherapy.
What CARTESIAN THERAPEUTICS INC does
Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for autoimmune diseases. The company leverages a proprietary technology platform to introduce mRNA into cells that can be dosed repeatedly without requiring pre-treatment chemotherapy, administered in an outpatient setting. It is currently focused on developing therapies for conditions like generalized myasthenia gravis (MG), where it is conducting a Phase 3 clinical trial (AURORA).
Themes: cell therapy / cellular medicine, autoimmune disease treatment, myasthenia gravis, mRNA therapeutics, precision immune reset
Fundamentals
- Price$10.04 as of 2026-08-21 close
- Market cap$304M as of 2026-08-21
- 1-year return-8.4% 2025-08-21 close $10.96 → 2026-08-21 close $10.04
- P/En/a negative earnings
- Net margin-8550.6% as of 2026-08-24
- ROE-3215.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-94.9% as of 2026-08-24
- Revenue CAGR (3y)-84.7% SEC XBRL
- Beta0.66 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How RNAC compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CARTESIAN THERAPEUTICS INC looks technically
CARTESIAN THERAPEUTICS INC (RNAC) is trading 32.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 32.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +32.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.98 | $8.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.57 | $7.57 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 7.27. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal | 36 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 32.6% above | +32.6% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 66.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($7.77 to $10.87) — its "stochastic" reading is 73 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 73.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.80 | $11.80 |
|---|---|---|
| From the 52-week high | it is 14.9% below its 52-week high (its highest price of the past year) | -14.9% |
| Above the 52-week low | it is 79.3% above its 52-week low (its lowest price of the past year) | +79.3% |
| Below the 52-week high | it is 14.9% below its highest point of the past year | 14.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $840.00 (set on 2016-11-28) | $840.00 |
| Given back of the 52-week move | over the past year its closes ranged ($5.84 to $11.25), and it has recovered well over two thirds of its fall from last year’s high — 78% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.18 to $9.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 77.6% |
| From the all-time high | it is 98.8% below its all-time high | -98.8% |
| Nearest price level | it is trading 4.5% below a resistance level at $10.49 — a price it turned at twice since 2025-08-20, most recently on 2025-09-30. Since 2024-08-21 it has 9 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.5% |
| All-time low | its lowest closing price on record is $5.60 (set on 2026-03-27) | $5.60 |
| Above the all-time low | it is 79.3% above its all-time low | +79.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 52nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.631 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.631 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.95 and $10.35 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.95 – $8.65 – $10.35 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 3.9 daily ranges above its 200-day average price (32.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.20× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Open gap | it gapped 3.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 9.2 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.3% |
| Gap filled | a 5.9% gap down opened on 2026-07-13 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 24 sessions to close | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.29% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 21.2 percentage points (the stock gained 23.5% while the market gained 2.3%) | +21.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 47.2 percentage points (the stock gained 50.3% while the market gained 3.1%) | +47.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 33.8 percentage points (the stock gained 44.9% while the market gained 11.1%) | +33.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 28.9 percentage points (the stock lost 8.4% while the market gained 20.5%) | -28.9% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.2% of the share price. | +11.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 28% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.87 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +27.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $9.62 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.4% |
Price levels it has turned at before
RNAC last closed at $10.04 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.49 | Resistance | 4.5% above the last close | turned there twice · 2025-08-20 to 2025-09-30 |
| $9.53 | Support | 5.1% below the last close | turned there twice · 2025-04-21 to 2025-05-09 |
| $9.34 | Support | 7.0% below the last close | turned there three times · 2025-06-23 to 2026-05-11 |
| $9.16 | Support | 8.8% below the last close | turned there three times · 2025-09-17 to 2025-12-15 |
| $10.93 | Resistance | 8.8% above the last close | turned there three times · 2025-09-05 to 2026-07-02 |
| $11.79 | Resistance | 17.5% above the last close | turned there three times · 2025-06-26 to 2025-08-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $7.27.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Broke out to a new 20-day high · beating the market · Just filled a gap (5%+ closed in the last week) · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.13 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$34.57 range $16.00 – $44.00; median $39.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RNAC
- Consensus EPS estimate-$1.01 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Development-stage company with no approved products; significant risk of never achieving profitability or successfully commercializing product candidates","Clinical trial execution risks including ability to enroll patients, successfully complete trials, and obtain regulatory approvals; unproven approach to therapeutic intervention in cell therapy for autoimmune diseases","Manufacturing complexity and scalability challenges for patient-specific cell therapies; dependence on third parties including contract research organizations for clinical trial conduct"]
What changed in the latest 10-Q
AI-assisted comparison of RNAC's 10-Q filed 2026-04-30 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for year ended December 31, 2025, filed March 9, 2026 (newer filing)
- Description of company as 'late clinical-stage' rather than 'clinical-stage' biotechnology company
- mRNA technology description: 'introduce mRNA into cells' (newer filing)
- Net loss of $39.2 million for three months ended March 31, 2026 and $17.7 million for three months ended March 31, 2025
- Accumulated deficit of $861.6 million as of March 31, 2026
- Bullet point: 'advance Descartes-08 for myositis into Phase 2 development'
- Grant revenue section: separate subsection describing grant revenue from specific research and development services
- Detailed breakdown of research and development expenses components
- Interest income section description
- Gain on change in fair value of warrant liabilities section
- (Loss) gain on change in fair value of contingent value right liability section
- Other (expense) income, net section header (text truncated)
- Removed:
- Reference to Form 10-K for year ended December 31, 2024, filed March 13, 2025 (older filing)
- Detailed Phase 2b clinical trial results with 83% participant improvement and 26-52 week durability language
- Entire 'Merger' section describing November 13, 2023 merger transaction details
- Details of 2023 Securities Purchase Agreement for Series A Preferred Stock ($60.25 million)
- Details of 2024 Securities Purchase Agreement for common stock and Series B Preferred Stock ($130.0 million)
- Net loss of $37.7 million for nine months ended September 30, 2025 and $67.2 million for nine months ended September 30, 2024
- Accumulated deficit of $729.8 million as of September 30, 2025
- Bullet point: 'continue to develop our preclinical and clinical-stage product candidates' (replaced with broader language in newer filing)
- Reworded:
- Company description changed from 'clinical-stage' to 'late clinical-stage' biotechnology company
- Overview section completely rewritten: removed detailed Phase 2b clinical trial data and patient results; replaced with simpler description of technology
- Removed specific merger details and transaction structure; merger section deleted entirely from newer filing
- Private placement financing details removed from Financial Operations section in newer filing
- Time periods changed from nine months ended September 30, 2025/2024 to three months ended March 31, 2026/2025
- Accumulated deficit reference date changed from September 30, 2025 to March 31, 2026
- Bullet point changed: 'continue to advance Descartes-08 for MG through Phase 3 development' expanded to include separate bullet for myositis Phase 2 advancement
- Notes:
- Older filing text is truncated at end of 'Collaboration and license revenue' section; full comparison of remaining sections not possible
- Newer filing text is truncated mid-sentence in 'Other (expense) income, net' section; full extent of that section cannot be assessed
- The filings cover different reporting periods (three months vs. nine months) which affects comparability of financial metrics
Risk Factors
- Added:
- Added to forward-looking statements: 'the potential impairment of our goodwill and indefinite lived intangible assets' (filed 2026-04-30)
- Added to forward-looking statements: 'our ability to monetize any of our legacy assets' moved to end of list (filed 2026-04-30)
- Removed:
- Removed: 'our ability to achieve the expected benefits or opportunities and related timing with respect to the Merger (as defined below) or to monetize any of our legacy assets' – replaced with separate items (filed 2026-04-30)
- Removed: reference to 'or CROs' expansion after 'contract research organizations' (filed 2026-04-30)
- Removed: 'from inflation, changes in interest rates, volatile market conditions, current or potential bank failures, and tariffs' – simplified to 'including inflation, increasing interest rates, volatile market conditions and current or potential bank failures' (filed 2026-04-30)
- Removed: 'and in the Middle East and geopolitical tensions in and with China' – changed to 'the ongoing conflict in the Middle East and geopolitical tensions with China' (filed 2026-04-30)
- Removed: 'our status as a preclinical and development-stage company' – changed to 'our status as a development-stage company' (filed 2026-04-30)
- Removed: 'our ability to access manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates' – simplified to 'our ability to receive or manufacture sufficient quantities of our product candidates' (filed 2026-04-30)
- Removed: 'the impact of pandemics or similar events on our operations, the continuity of our business, including our preclinical studies and clinical trials, and general economic conditions' as separate bullet point (filed 2026-04-30)
- Removed: 'and developments relating to our competitors and our industry, including the impact of government regulation and policy changes' – simplified to 'developments relating to our competitors and our industry' (filed 2026-04-30)
- Reworded:
- Changed 'contract research organizations, or CROs,' to 'contract research organizations' (filed 2026-04-30)
- Changed macroeconomic conditions language from detailed list to shorter list, removing tariffs reference (filed 2026-04-30)
- Changed geopolitical description from 'conflicts between Russia and Ukraine and in the Middle East' to 'ongoing conflicts between Russia and Ukraine, the ongoing conflict in the Middle East' (filed 2026-04-30)
- Changed 'our status as a preclinical and development-stage company' to 'our status as a development-stage company' (filed 2026-04-30)
- Notes:
- The balance sheet dates differ between filings (March 31, 2026 vs September 30, 2025), making financial statement comparison incomplete
- Forward-looking statements section shows reorganization of bullet points but substantial content overlap
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2026-01-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RNAC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RNAC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,776,616
- Reported value $10,926,189
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RNAC had 1,843,723 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RNAC had 6.09% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.89 days to cover at the same settlement.
- Reported short interest (shares) 1,843,723
- Short interest (% of shares outstanding) 6.09%
- Prior settlement (shares) 1,925,634
- Reported change -4.25%
- Days to cover (reported) 14.89
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- argenx (ARGX)
- UCB (UCBJY)
- Alexion Pharmaceuticals (AstraZeneca) (AZN)
- Amgen (AMGN)
- Johnson & Johnson (JNJ)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RNAC vs…
Frequently asked questions
What does CARTESIAN THERAPEUTICS INC (RNAC) do?
Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for autoimmune diseases. The company leverages a proprietary technology platform to introduce mRNA into cells that can be dosed repeatedly without requiring pre-treatment chemotherapy, administered in an outpatient setting. It is currently focused on developing therapies for conditions like generalized myasthenia gravis (MG), where it is conducting a Phase 3 clinical trial (AURORA).
What sector is CARTESIAN THERAPEUTICS INC (RNAC) in?
CARTESIAN THERAPEUTICS INC (RNAC) is classified in the Health Care sector. Its industry is Cell therapy for autoimmune diseases. It trades on NASDAQ.
Who are CARTESIAN THERAPEUTICS INC's (RNAC) competitors?
Notable peers of CARTESIAN THERAPEUTICS INC (RNAC) include argenx, UCB, Alexion Pharmaceuticals (AstraZeneca), Amgen and Johnson & Johnson. This peer set is informational only — not financial advice.
Is CARTESIAN THERAPEUTICS INC (RNAC) overbought or oversold right now?
CARTESIAN THERAPEUTICS INC (RNAC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RNAC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.